Evidence map›Paper›PMID 28942217›Full record

Trial reportJournal of psychiatric research2017

Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.

Douglas L Noordsy, Shirley M Glynn, Catherine A Sugar, Christopher D O'Keefe, Stephen R Marder

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychiatric research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Douglas L NoordsyDepartment of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, United States. Electronic address: dnoordsy@stanford.edu.
Shirley M GlynnSemel Institute for Neuroscience at UCLA, Los Angeles, CA, United States; VA Greater Los Angeles, Los Angeles, CA, United States.
Catherine A SugarSemel Institute for Neuroscience at UCLA, Los Angeles, CA, United States; Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA, United States.
Christopher D O'KeefeSouthern New Hampshire University, United States.
Stephen R MarderSemel Institute for Neuroscience at UCLA, Los Angeles, CA, United States; VA Greater Los Angeles, Los Angeles, CA, United States.

Funding

MANAGEMENT OF RISK FOR RELAPSE IN SCHIZOPHRENIAR01MH041573 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARDER, STEPHEN R · 1986 to 2004
$3.1M
NIMH NIH HHS R01 MH041573
6 · The paper itself

Abstract

This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment. A multicenter, randomized, double-blind trial was conducted among 107 outpatients with schizophrenia, who were cross-titrated to flexible dose risperidone or olanzapine over 2 weeks. Clinical endpoints included time to hospitalization and persistence on assigned medication. Weight, laboratory tests, psychopathology, neurologic side effects, social adjustment and role functioning were assessed at 3-6 month intervals. Data were analyzed first by randomized treatment, and then reassessed controlling for prior medication treatment. The proportion of patients on assigned medication at 18 months was 30.9% for risperidone and 37.3% for olanzapine. Mean doses were 6.4 ± 3.2 mg daily for risperidone, and 17.0 ± 5.0 mg daily for olanzapine. The groups did not differ significantly in time to medication discontinuation, first hospitalization or first employment. There were few differences in psychopathology, laboratory, or neurological assessments between groups at 18 months. Patients randomized to olanzapine gained modestly more weight. Controlling for pre-randomization medication suggested improvement in some aspects of psychopathology from switching medications; however, switching from olanzapine to risperidone was associated with more hospitalizations. Risperidone and olanzapine have similar efficacy and tolerability in patients with schizophrenia who are participating in supported employment. Randomization to olanzapine was associated with more weight gain, but randomization from olanzapine to risperidone appeared to be associated with a greater likelihood of hospitalization. Careful monitoring of metabolic effects and participation in supported employment may have contributed to minimal weight gain and metabolic effects.

Indexed as

Employment, SupportedOutcome Assessment, Health CareAdultAntipsychotic AgentsBenzodiazepinesDouble-Blind MethodFemaleHumansMaleMiddle AgedOlanzapineRisperidoneSchizophreniaWeight GainAntipsychotic AgentsBenzodiazepinesOlanzapineRisperidoneAntipsychotic medicationBMISchizophreniaSupported employment

Identifiers

PMID28942217
PMCPMC5653420

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.